source
- Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slideTyra Biosciences disclosed early phase 2 results for its FGFR3‑selective inhibitor dabogratinib in patients with low‑grade, intermediate‑risk non‑muscle‑invasive bladder cancer. The trial evaluate…
- Abbott receives FDA clearance for TactiFlex Duo catheter, offering flexible AFib ablation optionsAbbott announced that the U.S. Food and Drug Administration has cleared its new TactiFlex Duo catheter for use in atrial fibrillation ablation. The catheter can deliver pulsed field ablation, radi…Fierce Biotech · 1d agoRegulatoryPositive